Purpose To evaluate the pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs (NSAIDs) in the retinochoroidal tissues of rabbits. Methods The cyclooxygenase (COX) inhibitory activity of diclofenac, bromfenac, and amfenac, an active metabolite of nepafenac, were determined using human-derived COX-1 and COX-2. Each of the three NSAIDs was applied topically to rabbits, and after 0.5 to 8 hrs, the concentration of each drug in the aqueous humor and the retinochoroidal tissues was measured by liquid chromatography-tandem mass spectrometry. The pharmacokinetics of the drugs in the tissues after repeated doses as is done on patients was calculated by a simulation software. The inhibitory effect of each NSAID on the breakdown of the blood-retinal barrier was assessed by the vitreous protein concentration on concanavalin A-induced retinochoroidal inflammation in rabbits. Results The half-maximal inhibitory concentration (IC50) of diclofenac, bromfenac, and amfenac was 55.5, 5.56, and 15.3 nM for human COX-1, and 30.7, 7.45, and 20.4 nM for human COX-2, respectively. The three NSAIDs were detected in the aqueous humor and the retinochoroidal tissue at all-time points. Simulated pharmacokinetics showed that the levels of the three NSAIDs were continuously higher than the IC50 of COX-2, as an index of efficacy, in the aqueous humor, whereas only the bromfenac concentration was continuously higher than the IC50 at its trough level in the retinochoroidal tissues. The intravitreous concentration of proteins was significantly reduced in rabbits that received topical bromfenac (P = 0.026) but not the other two NSAIDs. Conclusions Topical bromfenac can penetrate into the retinochoroidal tissues in high enough concentrations to inhibit COX-2 and exerts its inhibitory effect on the blood-retinal barrier breakdown in an experimental retinochoroidal inflammation in rabbits. Topical bromfenac may have a better therapeutic benefit than diclofenac and nepafenac for retinochoroidal inflammatory diseases.
References
[1]
Pascolini D, Mariotti SP, Pokharel GP, Pararajasegaram R, Etya'ale D, et al. (2004) 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol 11: 67–115. doi: 10.1076/opep.11.2.67.28158
[2]
Congdon N, O'Colmain B, Klaver CC, Klein R, Mu？oz B, et al. (2004) Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122: 477–485. doi: 10.1001/archopht.122.4.477
[3]
Friedman DS, O'Colmain BJ, Mu？oz B, Tomany SC, McCarty C, et al. (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122: 564–572. doi: 10.1001/archopht.122.4.564
[4]
Miller JW, Le Couter J, Strauss EC, Ferrara N (2013) Vascular endothelial growth factor A in intraocular vascular disease. Ophthalmology 120: 106–114. doi: 10.1016/j.ophtha.2012.07.038
[5]
Do DV (2013) Implications of the comparisons of age-related macular degeneration treatments trials on clinical practice: what have we learned? Ophthalmology 120: S8–S10. doi: 10.1016/j.ophtha.2013.01.058
[6]
Freund KB, Mrejen S, Gallego-Pinazo R (2013) An update on the pharmacotherapy of neovascular age-related macular degeneration. Expert Opin Pharmacother 14: 1017–1028. doi: 10.1517/14656566.2013.787410
Polansky J, Weinreb R (1984) Steroids as anti-inflammatory agent. In: Sears M, editor. Pharmacology of the Eye. New York: Springer. pp. 460–583.
[9]
Raizman M (1996) Corticosteroid therapy of eye diseases. Fifty years later. Arch Ophthalmol 114: 1000–1001. doi: 10.1001/archopht.1996.01100140208016
[10]
Waterbury L, Kunysz EA, Beuerman R (1987) Effects of steroidal and non-steroidal anti-inflammatory agents on corneal wound healing. J Ocul Pharmacol 3: 43–54. doi: 10.1089/jop.1987.3.43
[11]
Schalnus R (2003) Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 217: 89–98. doi: 10.1159/000068563
[12]
Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR; Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group (2007) Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology 114: 1653–1662. doi: 10.1016/j.ophtha.2006.12.029
[13]
Uchio E, Itoh Y, Kadonosono K (2007) Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis. Ophthalmologica 221: 153–158. doi: 10.1159/000099294
[14]
Bucolo C, Melilli B, Piazza C, Zurria M, Drago F (2011) Ocular pharmacokinetics profile of different indomethacin topical formulations. J Ocul Pharmacol Ther 27: 571–576. doi: 10.1089/jop.2011.0120
[15]
Jones J, Francis P (2009) Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. Expert Opin Pharmacother 10: 2379–2385. doi: 10.1517/14656560903188425
[16]
Cho H, Wolf KJ, Wolf EJ (2009) Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol 3: 199–210. doi: 10.2147/opth.s4806
[17]
Yoshinaga N, Arimura N, Otsuka H, Kawahara K, Hashiguchi T, et al. (2011) NSAIDs inhibit neovascularization of choroid through HO-1-dependent pathway. Lab Invest 91: 1277–1290. doi: 10.1038/labinvest.2011.101
[18]
Gomi F, Sawa M, Tsujikawa M, Nishida K (2012) Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Retina 32: 1804–1810. doi: 10.1097/iae.0b013e31825be87f
[19]
Miyake K, Ogawa T, Tajika T, Gow JA, McNamara TR (2008) Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor. J Ocul Pharmacol Ther 24: 573–578. doi: 10.1089/jop.2007.0132
[20]
Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR (2008) 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther 24: 392–398. doi: 10.1089/jop.2007.0082
[21]
Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, et al. (1999) Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(？5H)-furanone]:a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290: 551–560. doi: 10.1016/s0960-894x(99)00288-7
[22]
Kapin MA, Yanni JM, Brady MT, McDonough TJ, Flanagan JG, et al. (2003) Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation 27: 281–291.
[23]
Walters T, Raizman M, Ernest P, Gayton J, Lehmann R (2007) In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg 33: 1539–1545. doi: 10.1016/j.jcrs.2007.05.015
[24]
Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM (2000) Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 24: 357–370.
[25]
Walsh DA, Moran HW, Shamblee DA, Uwaydah IM, Welstead WJ Jr, et al. (1984) Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenyl acetic acid and analogues. J Med Chem 11: 1379–1388. doi: 10.1021/jm00377a001
[26]
Kim SJ, Flach AJ, Jampol LM (2010) Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 55: 108–133. doi: 10.1016/j.survophthal.2009.07.005
[27]
Ruiz J, López M, Milà J, Lozoya E, Lozano JJ, et al. (1993) QSAR and conformational analysis of the antiinflammatory agent amfenac and analogues. J Comput Aided Mol Des 7: 183–198. doi: 10.1007/bf00126444
[28]
Ogawa T, Sakaue T, Terai T, Fukiage C (1995) Effects of bromfenac sodium, non-steroidal anti-inflammatory drug, on acute ocular inflammation. Nihon Ganka Gakkai Zasshi 99: 406–411.
[29]
Waterbury LD, Silliman D, Jolas T (2006) Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin 22: 1133–1140. doi: 10.1185/030079906x112471
[30]
Chastain JE (2003) General considerations in ocular drug delivery. In: Mitra AK, editor. Ophthalmic Drug Delivery Systems, Second edition, Revised and Expanded. New York: Marcel Dekker Inc. pp. 59–108.
[31]
Schoenwald RD, Ward RL (1978) Relationship between steroid permeability across excised rabbit cornea and octanol-water partition coefficients. J Pharm Sci 67: 786–788. doi: 10.1002/jps.2600670614
[32]
Singh P, Roberts MS (1994) Skin permeability and local tissue concentrations of nonsteroidal anti-inflammatory drugs after topical application. J Pharmacol Exp Ther 268: 144–151.
[33]
Ahuja M, Dhake AS, Sharma SK, Majumdar DK (2008) Topical ocular delivery of NSAIDs. AAPS J 10: 229–241. doi: 10.1208/s12248-008-9024-9
[34]
Ke TL, Graff G, Spellman JM, Yanni JM (2000) Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 24: 371–384.
[35]
Isaka M, Inada K, Tsutsumi S, Fushimi M, Inaba A, et al. (1999) Ocular tissue distribution in rabbit after instillation of bromfenac sodium ophthalmic solution. Drug Metab Pharmacokinet 14: 32–41. doi: 10.2133/dmpk.14.32
[36]
Ishii K, Matsuo H, Fukaya Y, Tanaka S, Sakaki H, et al. (2003) Iganidipine, a new water-soluble Ca2+ antagonist: ocular and periocular penetration after instillation. Invest Ophthalmol Vis Sci 44: 1169–1177. doi: 10.1167/iovs.02-0482
[37]
Mizuno K, Koide T, Shimada S, Mori J, Sawanobori K, et al. (2009) Route of penetration of topically instilled nipradilol into the ipsilateral posterior retina. Invest Ophthalmol Vis Sci 50: 2839–2847. doi: 10.1167/iovs.08-2922
[38]
Miyanaga M, Miyai T, Nejima R, Maruyama Y, Miyata K, et al. (2009) Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmol 87: 300–305. doi: 10.1111/j.1755-3768.2008.01433.x
[39]
Duong HV, Westfield KC, Chalkley TH (2007) Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. J Cataract Refract Surg 33: 1925–1929. doi: 10.1016/j.jcrs.2007.07.017
[40]
Yasuda K, Miyazawa A, Shimura M (2012) A comparison of preservative-free diclofenac and preserved diclofenac eye drops after cataract surgery in patients with diabetic retinopathy. J Ocul Pharmacol Ther 28: 283–289. doi: 10.1089/jop.2011.0133
[41]
Bucolo C, Marrazzo G, Platania CB, Romano GL, Drago F, et al. (2014) Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation. J Pharm Pharmacol: doi: 10.1111/jphp.12224.
[42]
Flaxel C, Schain MB, Hamon SC, Francis PJ (2012) Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study. Retina 32: 417–423. doi: 10.1097/iae.0b013e318229b0af
[43]
Gwon A, Mantras C, Gruber L, Cunanan C (1993) Concanavalin A-induced posterior subcapsular cataract: a new model of cataractogenesis. Invest Ophthalmol Vis Sci 34: 3483–3488.
[44]
Turgut B, Gül FC, Da？li F, Ilhan N, ？zgen M (2013) Impact of ghrelin on vitreous cytokine levels in an experimental uveitis model. Drug Des Devel Ther 7: 19–24. doi: 10.2147/dddt.s39453
